We are live on ! Find out more
ISEE

IVERIC bio, Inc. Common Stock

Delisted

ISEE was delisted on the 10th of July, 2023.

213 hedge funds and large institutions have $2.31B invested in IVERIC bio, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 57 funds opening new positions, 69 increasing their positions, 63 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

162% more call options, than puts

Call options by funds: $186M | Put options by funds: $70.8M

107% more capital invested

Capital invested by funds: $1.11B → $2.31B (+$1.2B)

104% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 28

43% more funds holding in top 10

Funds holding in top 10: 710 (+3)

16% more funds holding

Funds holding: 184213 (+29)

10% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 63

Holders
213
Holders Change
+29
Holders Change %
+15.76%
% of All Funds
3.67%
Holding in Top 10
10
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+42.86%
% of All Funds
0.17%
New
57
Increased
69
Reduced
63
Closed
28
Calls
$186M
Puts
$70.8M
Net Calls
+$115M
Net Calls Change
+$96.9M
Name Holding Trade Value Shares
Change
Change in
Stake
SFM
51
Sphera Funds Management
Israel
$10.4M -$5M -380,641 -40%
Fidelity Investments
52
Fidelity Investments
Massachusetts
$10.3M +$1.45M +110,809 +24%
ACP
53
Acuta Capital Partners
California
$10.1M
5VM
54
5AM Venture Management
California
$9.13M -$6.81M -519,027 -50%
RPAM
55
Rhenman & Partners Asset Management
Sweden
$8.73M +$1.51M +115,000 +46%
VC
56
Vivo Capital
California
$8.67M -$62.4M -4,755,221 -91%
GTC
57
Ghost Tree Capital
New York
$8.32M -$476K -36,300 -7%
Bank of New York Mellon
58
Bank of New York Mellon
New York
$7.99M +$790K +60,200 +16%
Connor, Clark & Lunn Investment Management (CC&L)
59
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$7.66M +$1.08M +82,644 +24%
Invesco
60
Invesco
Georgia
$7.25M +$4.51M +343,778 +571%
DCM
61
DAFNA Capital Management
California
$7.2M -$13.1K -1,000 -0.2%
IHAM
62
Integral Health Asset Management
New York
$6.73M +$4.92M +375,000 New
Bank of America
63
Bank of America
North Carolina
$6.72M +$1.29M +98,400 +36%
Rafferty Asset Management
64
Rafferty Asset Management
New York
$6.69M +$291K +22,146 +6%
Citigroup
65
Citigroup
New York
$6.32M -$123K -9,356 -3%
Barclays
66
Barclays
United Kingdom
$5.93M +$4.15M +316,278 +2,216%
Morgan Stanley
67
Morgan Stanley
New York
$5.82M -$7.02M -535,051 -62%
Susquehanna International Group
68
Susquehanna International Group
Pennsylvania
$5.6M +$1.56M +118,653 +61%
TIM
69
Thornburg Investment Management
New Mexico
$5.55M +$336K +25,605 +9%
PHS
70
PFM Health Sciences
California
$4.6M -$8.53M -649,732 -72%
WP
71
Woodline Partners
California
$4.54M +$3.32M +252,815 New
Group One Trading
72
Group One Trading
Illinois
$4.46M +$3.26M +248,505 New
Ameriprise
73
Ameriprise
Minnesota
$4.35M +$3.19M +242,663 New
MCM
74
Moore Capital Management
New York
$4.3M +$3.15M +239,944 New
PC
75
Pier Capital
Connecticut
$4.16M -$1.46M -110,905 -32%

ISEE Hedge Fund Activity: Q3 2022 in Review

213 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q3 2022, worth a combined $2.31B — up 107% from $1.11B a quarter earlier.

Buyers outnumbered sellers: 57 funds opened new ISEE positions and 28 closed out — a net gain of 29 holders — while 69 added to existing stakes and 63 trimmed.

The largest buyer was RTW Investments, opening a new position worth an estimated $47.6M. The largest seller was Vivo Capital, cutting an estimated $62.4M.

  • 213 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q3 2022, up from 184 in Q2 2022.
  • Funds reported $2.31B of IVERIC bio, Inc. Common Stock stock for Q3 2022, up 107% quarter-over-quarter.
  • 57 funds opened new IVERIC bio, Inc. Common Stock positions in Q3 2022 and 28 closed out, a net change of +29 holders.
  • The largest IVERIC bio, Inc. Common Stock buyer in Q3 2022 was RTW Investments, an estimated $47.6M added.
  • The largest IVERIC bio, Inc. Common Stock seller in Q3 2022 was Vivo Capital, an estimated $62.4M sold.

Based on aggregated 13F filings for Q3 2022.